Gilead Sciences, Inc.
Compare market positioning with top industry peers
Explore Gilead Sciences
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1987 in Foster City, California
In the cell therapy space, the company faces intense competition from Bristol Myers Squibb, which has launched Abecma and Carvykti in the multiple myeloma space, and from a new wave of allogeneic cell therapy companies that are attempting to eliminate the complex autologous manufacturing process. The origin of Gilead Sciences, Inc. is not a single founding moment but a complex evolution of scientific discovery, entrepreneurial ambition, and the brutal economics of the global antiviral market. The story begins in 1987 when Michael L. Riordan, a physician and entrepreneur, founded the company in Foster City, California, with an initial focus on developing antifungal therapies for life-threatening infections.
Gilead Sciences possesses an academic, mission-driven founding story, rooted in the uncertainty of the early HIV/AIDS epidemic and the ambitious application of emerging antiviral science. The company was founded in 1987 in Foster City, California, by Dr. Michael Riordan. Riordan was brilliant, holding degrees from both Washington University and Johns Hopkins School of Medicine, and he had also worked in venture capital. When he founded Gilead (at just 29 years old), the biotech landscape was heavily dominated by companies focusing on proteins and complex antibodies. Riordan, however, had a personal and foundational focus: antivirals. Having survived a severe bout of dengue fever while working in a clinic in the Philippines he was obsessed with developing drugs that could stop deadly viruses from replicating. He founded Gilead (named after the 'Balm of Gilead,' a healing ointment from the Bible) with exactly $2 million in venture capital. The early years were intensely difficult, characterized by scientific failures and a complete lack of revenue. However, the foundational masterstroke occurred in the 1990s when Gilead developed expertise in nucleotide analogs—compounds that essentially mimic the building blocks of DNA to trick and destroy viruses. This scientific breakthrough culminated in the development of Tenofovir, the foundational drug for the modern treatment of HIV. By focusing on complex, targeted antivirals rather than chasing broader biotech trends, Riordan established the foundational architecture that eventually allowed Gilead to revolutionize the treatment of HIV, Hepatitis B, and eventually Hepatitis C, cementing its status as one of the most impactful pharmaceutical companies in modern history.
Michael L. Riordan founded Gilead Sciences in Foster City, California, with an initial focus on developing antifungal therapies for life-threatening infections.
Gilead Sciences executed a desperate IPO that raised $86 million, providing the necessary lifeline to continue operations and pivot to antivirals after facing a severe cash crunch.
The FDA approved Viread (tenofovir disoproxil fumarate), the first once-daily nucleotide reverse transcriptase inhibitor for HIV, marking the beginning of Gilead's ascent to the top of the global virology hierarchy.
Gilead acquired Triangle Pharmaceuticals for $464 million, securing the rights to emtricitabine which was combined with tenofovir to create Truvada, the most successful HIV prevention and treatment regimen in history.
Gilead acquired Pharmasset for $11 billion, securing the nucleotide analog platform responsible for Sovaldi and Harvoni, which generated over $50 billion in cumulative revenue.
Gilead acquired Kite Pharma for $11.9 billion, establishing a dominant position in autologous CAR-T cell therapy with Yescarta and expanding its presence in oncology.
Gilead acquired Immunomedics for $21 billion, securing the Sacituzumab govitecan (Trodelvy) platform and establishing a dominant position in the antibody-drug conjugate (ADC) space.
Gilead reported $28.9 billion in product sales for FY2025, with operating income reaching $10.2 billion and free cash flow at $9.8 billion, demonstrating strong performance post-Veklury decline.
Gilead announced the results of the PURPOSE 1 trial, demonstrating 100% efficacy for lenacapavir in preventing HIV acquisition in cisgender women, a landmark result in HIV prevention.
Gilead acquired Immunomedics for $21 billion to gain control of the Sacituzumab govitecan (Trodelvy) ADC platform, establishing a dominant position in solid tumor oncology.
Gilead acquired Kite Pharma for $11.9 billion to establish a dominant position in autologous CAR-T cell therapy with Yescarta and expand its presence in oncology.
Gilead acquired Pharmasset for $11 billion to secure the nucleotide analog platform responsible for Sovaldi and Harvoni, the curative hepatitis C therapies.
Gilead acquired Forty Seven for $4.9 billion to gain control of the CD47 blocker magrolimab, a novel oncology asset targeting myelodysplastic syndromes and acute myeloid leukemia.
Since its establishment in 1987, Gilead Sciences, Inc. expanded from an early-stage venture into a recognized leader in Biotechnology, overcoming key market challenges.
Over its history, Gilead Sciences, Inc. executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.
By continually modernizing operations and embracing workflow automation, Gilead Sciences, Inc. maintains resilience through changing technological and economic cycles.